US Patent 11,357,753: What Is Claimed, How Broad the Coverage Is, and Where It Sits in the PONV Landscape
US Drug Patent 11,357,753 claims a method of treating postoperative nausea and/or vomiting (PONV) using amisulpride at a defined 10 mg dose in a post-surgical patient who has already received a prophylaxis anti-PONV drug that is not amisulpride and who then experiences PONV prior to the amisulpride administration. The claims also add further limitations around the type of prophylaxis drug, which additional anti-emetics may be co-administered, amisulpride form, and route.
The operative claim-set is method-based, combination-adjacent, and tightly anchored to the clinical sequence (prophylaxis first, then PONV, then amisulpride rescue). This creates a narrower infringement footprint than a prophylaxis-first or broad “use in PONV” formulation, but it can still matter if a product is positioned as rescue therapy after breakthrough PONV.
What Is the Core Independent Claim Covering? (Claim 1)
Claim 1 elements (conjunctive)
Claim 1 recites a method with the following required features:
-
Indication and patient state
- Treat a patient with postoperative nausea and/or vomiting (PONV).
- The patient has undergone a surgical procedure.
- The patient experienced PONV prior to amisulpride administration.
-
Sequence relative to prophylaxis
- The patient has been administered a prophylaxis drug for PONV.
- That prophylaxis drug is not amisulpride.
-
Active dose and drug identity
- Administer amisulpride.
- Dose is specifically 10 mg.
-
Route and formulation
- These are not in Claim 1, but are limited in dependent claims (see below).
Practical claim construction implications
- Rescue-only posture: Because Claim 1 requires that the patient “experienced PONV prior to the administration of amisulpride,” the claim is structured around breakthrough PONV treatment rather than prevention.
- Prophylaxis must exist and be non-amisulpride: The claim requires prior prophylaxis with a drug other than amisulpride. A regimen that uses amisulpride as part of prophylaxis would fall outside Claim 1 as written.
- Dose lock: The claim is anchored to 10 mg. Lower or higher dosing is not covered unless the claim is interpreted to encompass dosing variations (not indicated by the text provided).
How Much Does Claim Scope Narrow in Dependent Claims? (Claims 2-8)
Claim 2: Prophylaxis drug cannot be a D2 antagonist
- Adds: prophylaxis drug is not a dopamine-2 (D2) antagonist.
Scope effect: This reduces coverage to patients whose prophylaxis regimen is non-D2-antagonist. If a prophylaxis protocol includes agents with D2 antagonist activity (for example, many antipsychotic-class antiemetics), that scenario can become non-infringing for Claim 2.
Claim 3: Prophylaxis drug category limits
- Adds: prophylaxis drug is an anti-emetic selected from:
- 5HT3-antagonist
- corticosteroid
- anti-histamine (H1)
- anti-cholinergic
- H2-antagonist
- NK1-antagonist
Scope effect: Claim 3 is broader than Claim 2 in that it permits prophylaxis from multiple mechanistic classes, but it still excludes prophylaxis drugs that are not within the enumerated set.
Claim 4: Allows amisulpride plus another anti-emetic
- Adds: amisulpride is administered in combination with another anti-emetic, either sequentially or simultaneously.
Scope effect: This is a combination expansion, but the “another anti-emetic” must exist. The claim reads like it tolerates multi-drug rescue protocols.
Claim 5 and Claim 6: Limit the “another anti-emetic” to specified classes and exemplars
- Claim 5 limits the “another anti-emetic” to:
- 5HT3 antagonist
- NK1 antagonist
- steroid
- Claim 6 further specifies examples of that “another anti-emetic” as one of:
- dexamethasone
- ondansetron
- granisetron
- palonosetron
- aprepitant
- netupitant
- rolapitant
Scope effect: These dependent claims operationalize the combination window into commonly used PONV prophylaxis/rescue mechanistic classes, including the 5HT3 and NK1 pathways plus steroids.
Claim 7: Amisulpride substantially as a racemate
- Adds: amisulpride is administered “substantially in the form of a racemate.”
Scope effect: This matters if the landscape includes enantiomerically-pure versions, salt variants, or stereoisomer-specific preparations. As written, the claim targets compositions where amisulpride is effectively not separated into a single enantiomer form.
Claim 8: Intravenous route
- Adds: administer amisulpride via the intravenous (IV) route.
Scope effect: If the accused product uses oral, intramuscular, sublingual, rectal, inhaled, or other routes, Claim 8 would not read. If the claim is asserted via Claim 1 without relying on Claim 8, IV is not required in Claim 1, but Claim 8 strengthens product-specific infringement arguments where IV dosing is part of the protocol.
Claim Coverage Map: What Scenarios Do (and Don’t) Fit?
In-scope scenarios (high confidence from claim text)
| Scenario feature |
What Claim language requires |
| Patient timing |
Has surgery, then experiences PONV before amisulpride |
| Prophylaxis prerequisite |
Patient had prophylaxis for PONV that is not amisulpride |
| Drug and dose |
Amisulpride 10 mg |
| Combination permissibility |
Another anti-emetic may be used (Claim 4), including specific agents in later dependents |
| Route |
IV required only for Claim 8 |
Common design-outs (can avoid infringement)
| Design-out |
Why it can avoid the claim set |
| Use amisulpride in prophylaxis |
Claim 1 requires prophylaxis is not amisulpride |
| Rescue dose not equal to 10 mg |
Claim 1 is dose-anchored to 10 mg |
| No prophylaxis pre-treatment |
Claim 1 requires prophylaxis drug was administered prior to the event |
| D2-antagonist prophylaxis for Claim 2 specifically |
Claim 2 excludes D2 antagonists (Claim 3 can still apply if within enumerated classes) |
| Non-IV route strategy for Claim 8 |
Claim 8 requires IV |
What Does This Mean for the Patent Landscape? (Competitive Positioning)
1) It is a method patent for breakthrough PONV, not broad prophylaxis
Most PONV patent families typically target:
- prophylactic regimens (pre-op dosing),
- fixed-dose combinations for prevention,
- anesthetic-sparing or risk-factor frameworks,
- formulation innovations.
US 11,357,753 is centered on treatment with defined dosing after prophylaxis and after PONV onset. That shifts the competitive relevance to:
- clinical pathways where prophylaxis is standard and
- “rescue” therapy is triggered after symptom onset.
2) The claim set tracks standard mechanistic classes used in PONV
Claim 3 and Claim 6 explicitly map onto commonly used PONV mechanistic categories:
- 5HT3 antagonists: ondansetron, granisetron, palonosetron
- NK1 antagonists: aprepitant, netupitant, rolapitant
- steroids: dexamethasone
- plus other antiemetic classes for prophylaxis: H1, anticholinergic, H2
That suggests the patent is designed to read across routine clinical prophylaxis combinations rather than a single proprietary prophylaxis.
3) Narrowing via patient sequence and dose
The two largest narrowing levers are:
- sequencing (PONV occurred before amisulpride),
- dose (10 mg).
Those levers reduce the likelihood that routine PONV prophylaxis regimens would infringe. They also raise the likelihood that infringement assertions would depend on precise protocol adherence in clinical practice.
4) Combination claim path provides multiple infringement angles
Claim 4 through Claim 6 allow infringement theories tied to common rescue combinations:
- amisulpride plus ondansetron/granisetron/palonosetron,
- amisulpride plus aprepitant/netupitant/rolapitant,
- amisulpride plus dexamethasone.
This reduces the space for “avoidance by refusing combination therapy,” because the claim allows sequential or simultaneous combinations.
5) Product form and route create additional seams
- Claim 7 can matter if a competitor or developer uses a different stereochemistry approach (rare for conventional formulations, but relevant if any stereoselective technology exists).
- Claim 8 can matter if any planned product uses non-IV administration.
Scope Likely to Attract Litigation vs. Scope Likely to Be Practically Avoidable
Most litigation-attractive claim features
- 10 mg is specific enough to frame an infringement comparison.
- rescue after breakthrough PONV maps onto a distinct clinical step with observable outcomes and dosing records.
- Dependent claims enumerate common concomitant agents, allowing clear mapping to real-world prophylaxis/rescue workflows.
Most practical avoidance levers
- Changing the rescue dose away from 10 mg.
- Using amisulpride in prophylaxis (so “prophylaxis drug is not amisulpride” fails).
- Using non-IV routes where Claim 8 is relied upon.
A Structured Read of the Claim Set: What Each Claim Adds
- Claim 1 (independent): Breakthrough PONV treatment with amisulpride 10 mg after prophylaxis with a non-amisulpride drug; PONV already occurred.
- Claim 2: Prophylaxis is not a D2 antagonist.
- Claim 3: Prophylaxis is one of specified antiemetic classes including 5HT3, corticosteroid, H1, anticholinergic, H2 antagonist, NK1.
- Claim 4: Adds combination flexibility: another anti-emetic, sequential or simultaneous.
- Claim 5: Restricts that “another anti-emetic” class to 5HT3, NK1, or steroid.
- Claim 6: Lists specific agents (dexamethasone, ondansetron, granisetron, palonosetron, aprepitant, netupitant, rolapitant).
- Claim 7: Amisulpride substantially as racemate.
- Claim 8: IV administration.
Key Takeaways
- US 11,357,753 is a breakthrough PONV method patent: it requires PONV onset before amisulpride administration and mandates prior prophylaxis with a non-amisulpride antiemetic.
- Coverage is dose-anchored to 10 mg and is structurally narrower than prophylaxis-first claims.
- Dependent claims expand infringement pathways through common PONV mechanistic classes (5HT3, NK1, steroids) while adding constraints on prophylaxis mechanism, combination scope, amisulpride stereochemistry, and IV route.
- From a competitive lens, protocol design choices that can avoid the claim set are: not using 10 mg, avoiding the required prophylaxis sequence, using amisulpride as part of prophylaxis, or avoiding IV where Claim 8 is asserted.
FAQs
-
Is US 11,357,753 limited to prophylaxis regimens?
No. It is limited to treatment of PONV where the patient already experienced PONV prior to giving amisulpride, after a non-amisulpride prophylaxis.
-
Does the patent require a specific prophylaxis drug?
It requires a prophylaxis drug for PONV that is not amisulpride (Claim 1). Dependent claims further restrict prophylaxis to certain mechanisms or classes (Claims 2-3).
-
What is the key dosing term competitors will focus on?
The rescue dose in Claim 1 is amisulpride 10 mg, which is the central dose limitation.
-
Can amisulpride be given with other antiemetics?
Yes. Claim 4 allows combination with another antiemetic sequentially or simultaneously, and Claims 5-6 specify the permitted classes and exemplars.
-
Does the claim require intravenous dosing?
Only for Claim 8. Claim 1 does not specify route in the provided text; Claim 8 limits to IV.
References
[1] US Patent 11,357,753 (claims provided in prompt).
